Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 630397, 16 pages
http://dx.doi.org/10.1155/2015/630397
Research Article

Curcumin Enhanced Busulfan-Induced Apoptosis through Downregulating the Expression of Survivin in Leukemia Stem-Like KG1a Cells

1Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510000, China
2Department of Hematology, Jiangmen Wuyi Traditional Chinese Medicine Hospital, Jiangmen 529000, China
3Department of hemodialysis, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, China

Received 28 February 2015; Accepted 24 April 2015

Academic Editor: Pratheeshkumar Poyil

Copyright © 2015 Guangyang Weng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. K. Hamilton and E. A. Copelan, “Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia,” Stem Cells, vol. 30, no. 8, pp. 1581–1586, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. G. L. Phillips, “Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?” Leukemia Research, vol. 36, no. 12, pp. 1490–1495, 2012. View at Publisher · View at Google Scholar
  3. A. Sureda, M. I. B. Pereira, and P. Dreger, “The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma,” Current Opinion in Oncology, vol. 24, no. 6, pp. 727–732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. E. D. Thomas, “A review of the results of human marrow transplantation in Seattle,” Nihon Ketsueki Gakkai Zasshi, vol. 40, pp. 863–872, 1977. View at Google Scholar
  5. S. Z. Pavletic, S. Kumar, M. Mohty et al., “NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the epidemiology and natural history of relapse following allogeneic cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 16, no. 7, pp. 871–890, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Yoshihara, T. Ando, and H. Ogawa, “Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse,” Biology of Blood and Marrow Transplantation, vol. 18, no. 12, pp. 1800–1807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. L. Linenberger, T. Hong, D. Flowers et al., “Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin,” Blood, vol. 98, no. 4, pp. 988–994, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Pei and C. T. Jordan, “How close are we to targeting the leukemia stem cell?” Best Practice and Research: Clinical Haematology, vol. 25, no. 4, pp. 415–418, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Fuchs, V. Daniel, M. Sadeghi, G. Opelz, and C. Naujokat, “Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells,” Biochemical and Biophysical Research Communications, vol. 394, no. 4, pp. 1098–1104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. She, X. Niu, X. Chen et al., “Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity,” Cancer Letters, vol. 318, no. 2, pp. 173–179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Mohty, F. Malard, D. Blaise et al., “Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial,” Cancer, vol. 121, no. 4, pp. 562–569, 2015. View at Publisher · View at Google Scholar
  14. S. Almog, D. Kurnik, A. Shimoni et al., “Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination,” Biology of Blood and Marrow Transplantation, vol. 17, no. 1, pp. 117–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Jiao, J. T. Wilkinson, X. Di et al., “Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator,” Blood, vol. 113, no. 2, pp. 462–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. van't Land, N. M. A. Blijlevens, J. Marteijn et al., “Role of curcumin and the inhibition of NF-ΚB in the onset of chemotherapy-induced mucosal barrier injury,” Leukemia, vol. 18, no. 2, pp. 276–284, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Li and T. Zhang, “Targeting cancer stem cells by curcumin and clinical applications,” Cancer Letters, vol. 346, no. 2, pp. 197–205, 2014. View at Publisher · View at Google Scholar
  18. A. Goel and B. B. Aggarwal, “Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs,” Nutrition and Cancer, vol. 62, no. 7, pp. 919–930, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. H. Rahmani, M. A. Al Zohairy, S. M. Aly, and M. A. Khan, “Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways,” BioMed Research International, vol. 2014, Article ID 761608, 15 pages, 2014. View at Publisher · View at Google Scholar
  20. M. M. Ho, D. E. Hogge, and V. Ling, “MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia,” Experimental Hematology, vol. 36, no. 4, pp. 433–442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. G.-M. Zou, “Cancer stem cells in leukemia, recent advances,” Journal of Cellular Physiology, vol. 213, no. 2, pp. 440–444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Ruggeri, A. Mancusi, M. Capanni et al., “Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value,” Blood, vol. 110, no. 1, pp. 433–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. C. Stubbs and S. A. Armstrong, “Therapeutic implications of leukemia stem cell development,” Clinical Cancer Research, vol. 13, no. 12, pp. 3439–3442, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Bonnet and J. E. Dick, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–737, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Gerber, B. D. Smith, B. Ngwang et al., “A clinically relevant population of leukemic CD34+CD38-cells in acute myeloid leukemia,” Blood, vol. 119, no. 15, pp. 3571–3577, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Hu, D. Cao, Y. Li, Y. He, and K. Guo, “Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors,” Cancer Biology and Therapy, vol. 13, no. 7, pp. 516–526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Sánchez, G. P. Simón, E. Calviño, E. de Blas, and P. Aller, “Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 114–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Y.-K. Kwon, J.-M. Jun, S.-W. Shin, J.-W. Cho, and S.-I. Suh, “Curcumin decreases cell proliferation rates through BTG2-mediated cyclin D1 down-regulation in U937 cells,” International Journal of Oncology, vol. 26, no. 6, pp. 1597–1603, 2005. View at Google Scholar · View at Scopus
  29. S. Derochette, T. Franck, A. Mouithys-Mickalad, G. Deby-Dupont, P. Neven, and D. Serteyn, “Intra- and extracellular antioxidant capacities of the new water-soluble form of curcumin (NDS27) on stimulated neutrophils and HL-60 cells,” Chemico-Biological Interactions, vol. 201, no. 1–3, pp. 49–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-C. Wu, C.-S. Lai, V. Badmaev, K. Nagabhushanam, C.-T. Ho, and M.-H. Pan, “Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK signaling pathways in human leukemia HL-60 cells,” Molecular Nutrition and Food Research, vol. 55, no. 11, pp. 1646–1654, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Zhou, L. Ye, Y. Bai et al., “Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: a novel curcumin analog,” PLoS ONE, vol. 9, Article ID e107876, 2014. View at Publisher · View at Google Scholar
  32. C. Kantara, M. O'Connell, S. Sarkar, S. Moya, R. Ullrich, and P. Singh, “Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA,” Cancer Research, vol. 74, no. 9, pp. 2487–2498, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. M. S. Charpentier, R. A. Whipple, M. I. Vitolo et al., “Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment,” Cancer Research, vol. 74, no. 4, pp. 1250–1260, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Anand, C. Sundaram, S. Jhurani, A. B. Kunnumakkara, and B. B. Aggarwal, “Curcumin and cancer: an ‘old-age’ disease with an ‘age-old’ solution,” Cancer Letters, vol. 267, no. 1, pp. 133–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Park, V. Ayyappan, E.-K. Bae et al., “Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells,” Molecular Oncology, vol. 2, no. 4, pp. 317–326, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Yu, S. S. Kanwar, B. B. Patel, J. Nautiyal, F. H. Sarkar, and A. P. N. Majumdar, “Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX,” Translational Oncology, vol. 2, no. 4, pp. 321–328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Srimuangwong, C. Tocharus, J. Tocharus, A. Suksamrarn, and P. Y. Chintana, “Effects of hexahydrocurcumin in combination with 5-fuorouracil on dimethylhydrazine-induced colon cancer in rats,” World Journal of Gastroenterology, vol. 18, no. 47, pp. 6951–6959, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Faião-Flores, J. A. Q. Suarez, P. C. Pardi, and D. A. Maria, “DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment,” Tumor Biology, vol. 33, no. 3, pp. 775–785, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. X.-Y. Zhang, Q.-X. Bai, G.-S. Huang, H. Zhao, J.-J. Chen, and L.-J. Yang, “Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 19, no. 3, pp. 684–688, 2011. View at Google Scholar · View at Scopus
  40. T. Nakane, H. Nakamae, H. Koh et al., “Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation,” International Journal of Hematology, vol. 93, no. 4, pp. 509–516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. J.-Y. Wang, P. Yu, S. Chen et al., “Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction,” Molecular Oncology, vol. 7, no. 5, pp. 907–916, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. U. Testa, “Leukemia stem cells,” Annals of Hematology, vol. 90, no. 3, pp. 245–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Sehl, H. Zhou, J. S. Sinsheimer, and K. L. Lange, “Extinction models for cancer stem cell therapy,” Mathematical Biosciences, vol. 234, no. 2, pp. 132–146, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  44. S. W. Lane, D. T. Scadden, and D. G. Gilliland, “The leukemic stem cell niche: current concepts and therapeutic opportunities,” Blood, vol. 114, no. 6, pp. 1150–1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. E. C. Zeestraten, A. Benard, M. S. Reimers et al., “The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry,” Biomarkers in Cancer, vol. 5, pp. 13–29, 2013. View at Publisher · View at Google Scholar
  46. B. P. Eckelman, G. S. Salvesen, and F. L. Scott, “Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family,” EMBO Reports, vol. 7, no. 10, pp. 988–994, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. E. Choi, M. Butterworth, S. Malladi, C. S. Duckett, G. M. Cohen, and S. B. Bratton, “The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing,” The Journal of Biological Chemistry, vol. 284, no. 19, pp. 12772–12782, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. M. Verhagen, J. Silke, P. G. Ekert et al., “HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins,” The Journal of Biological Chemistry, vol. 277, no. 1, pp. 445–454, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Miguel Martins, I. Iaccarino, T. Tenev et al., “The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a Reaper-like motif,” Journal of Biological Chemistry, vol. 277, no. 1, pp. 439–444, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Sekine, Y. Hao, Y. Suzuki, R. Takahashi, T. Tsuruo, and M. Naito, “HtrA2 cleaves Apollon and induces cell death by IAP-binding motif in Apollon-deficient cells,” Biochemical and Biophysical Research Communications, vol. 330, no. 1, pp. 279–285, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. C. H. A. Cheung, C.-C. Huang, F.-Y. Tsai et al., “Survivin—biology and potential as a therapeutic target in oncology,” OncoTargets and Therapy, vol. 6, pp. 1453–1462, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Bongiovanni, F. Di Diodoro, S. L. Della, and C. Brachelente, “On the role of survivin as a stem cell biomarker of canine hair follicle and related tumours,” Veterinary Dermatology, vol. 25, no. 2, pp. 138–141, e39–e40, 2014. View at Publisher · View at Google Scholar
  53. J. R. Kanwar, G. Mahidhara, K. Roy et al., “Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc,” Nanomedicine, vol. 10, no. 1, pp. 35–55, 2015. View at Publisher · View at Google Scholar
  54. S. Fukuda, M. Abe, C. Onishi et al., “Survivin selectively modulates genes deregulated in human leukemia stem cells,” Journal of Oncology, vol. 2011, Article ID 946936, 14 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Gedaly, R. Galuppo, M. F. Daily et al., “Targeting the Wnt/beta-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535,” PLoS ONE, vol. 9, no. 6, Article ID e99272, 2014. View at Publisher · View at Google Scholar
  56. R. Galuppo, E. Maynard, M. Shah et al., “Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/beta-catenin pathways,” Anticancer Research, vol. 34, pp. 1709–1713, 2014. View at Google Scholar